Stanford Cancer Institute

Cancer Cell Therapy

CAR-T Therapies for Aggressive Large Cell Lymphoma
Age ≥ 18 yrs

- CAR Therapies Following Prior CAR Therapy
- Expanded Access Protocols for Commercial CAR-T Products Manufactured of Specification
- 3rd Line CAR Therapies

CCT5029
Phase 1/II Autologous CD22+ CAR-T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
 PI: Muffy Sponsor: Stanford University

CCT5051
Phase I ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta T Cells +/- IL-2 in B Cell Malignancies
 PI: Miklos Sponsor: Adicet Bio, Inc.

CCT5016
Managed Access Program (MAP) CTL019 in ALL or DLBCL
 PI: Miklos Sponsor: Novartis

CCT5044
Phase I Open-label, Multicenter KITE-563 (Autologous Anti-CD19/CD20 CAR T-Cell Therapy) in Relapsed and/or Refractory B-Cell Lymphoma
 PI: Dahija Sponsor: Kite Pharma, Inc.
 Priority 1

CCT5042
Phase II Anti-CD20 & Anti-CD19 Specific Chimeric Antigen Receptor in Relapsed and/or Refractory DLBCL
 PI: Miklos Sponsor: Miltenyi Biomedicine, GmbH

CCT5038
Pilot 18-F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
 PI: Miklos Sponsor: Stanford University

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu